Stock listing

Frankfurt:1C0 Celyad Oncology SA Aktie

German listing (Frankfurt) of Celyad Oncology SA · home listing Euronext:CYAD

Follow Celyad Oncology SA into a list and get an email when it puts out news.

Share price · FWB:1C0

€0.121 EUR 0.000 (0.0%)

Close on Nov 20, 2026

Past year -45.1% · daily closes, Nov 20, 2025 – Nov 17, 2026, adjusted for splits
Day range
€0.121 – €0.121 EURNov 20, 2026
Market cap
€2.23M EURAt the close on Nov 20, 2026 · price × 18.46M shares outstanding
52-week range
€0.100 – €0.453 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€2 EURMedian day 0 shares · 63 days with no trades · last 3 months, Aug 20, 2026 – Nov 17, 2026
Celyad Oncology SA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Euronext:CYAD · Home€0.162 EUR-0.013 (-7.4%)4,985€0.161€0.163€0.145€0.175Close on Nov 20, 2026
Frankfurt:1C0€0.121 EUR0.000 (0.0%)—€0.121€0.121€0.121€0.121Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 17, 2026 · FWB:1C0 · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.100-0.026-20.6%€0.100€0.100€0.1000
€0.126-0.004-3.1%€0.126€0.126€0.1260
€0.130-0.008-5.8%€0.130€0.130€0.1300
€0.138+0.008+6.2%€0.138€0.138€0.1380
€0.130-0.010-7.1%€0.130€0.130€0.1300
€0.140+0.002+1.4%€0.140€0.140€0.1400
€0.138-0.001-0.7%€0.138€0.138€0.1380
€0.139-0.004-2.8%€0.139€0.139€0.1390
€0.143-0.014-8.9%€0.143€0.143€0.1430
€0.157-0.002-1.3%€0.157€0.157€0.1570
€0.159-0.002-1.2%€0.159€0.159€0.1590
€0.161-0.009-5.3%€0.161€0.161€0.1610
€0.170+0.001+0.6%€0.170€0.170€0.1700
€0.1690.0000.0%€0.169€0.169€0.1690
€0.169+0.002+1.2%€0.169€0.169€0.1690
€0.167+0.001+0.6%€0.167€0.167€0.1670
€0.166-0.002-1.2%€0.166€0.166€0.1660
€0.168-0.017-9.2%€0.168€0.168€0.1680
€0.185+0.016+9.5%€0.185€0.185€0.1850
€0.169+0.002+1.2%€0.169€0.169€0.1690
€0.167-0.021-11.2%€0.167€0.167€0.1670
€0.188+0.015+8.7%€0.188€0.188€0.1880
€0.173+0.008+4.8%€0.173€0.173€0.1730
€0.165-0.014-7.8%€0.165€0.165€0.1650
€0.179+0.010+5.9%€0.179€0.179€0.1790
€0.169+0.009+5.6%€0.169€0.169€0.1690
€0.160-0.028-14.9%€0.160€0.160€0.1600
€0.188+0.010+5.6%€0.188€0.188€0.1880
€0.178-0.002-1.1%€0.178€0.178€0.1780
€0.1800.0000.0%€0.180€0.180€0.1800
€0.180-0.005-2.7%€0.180€0.180€0.1800
€0.185+0.005+2.8%€0.185€0.185€0.1850
€0.180-0.001-0.6%€0.180€0.180€0.1800
€0.181-0.007-3.7%€0.181€0.181€0.1810
€0.188+0.003+1.6%€0.188€0.188€0.1880
€0.185-0.010-5.1%€0.185€0.185€0.1850
€0.195-0.015-7.1%€0.195€0.195€0.1950
€0.210-0.001-0.5%€0.210€0.210€0.2100
€0.211+0.019+9.9%€0.211€0.211€0.2110
€0.192-0.018-8.6%€0.192€0.192€0.1920
€0.210+0.010+5.0%€0.210€0.210€0.2100
€0.200-0.078-28.1%€0.200€0.200€0.2000
€0.278+0.077+38.3%€0.203€0.280€0.203420
€0.201-0.021-9.5%€0.201€0.201€0.2010
€0.222+0.037+20.0%€0.222€0.222€0.2220
€0.185-0.033-15.1%€0.185€0.185€0.1850
€0.218-0.001-0.5%€0.218€0.218€0.2180
€0.219-0.016-6.8%€0.219€0.219€0.2190
€0.235+0.013+5.9%€0.235€0.235€0.2350
€0.222-0.010-4.3%€0.222€0.222€0.2220
€0.232+0.011+5.0%€0.232€0.232€0.2320
€0.2210.0000.0%€0.221€0.221€0.2210
€0.221-0.013-5.6%€0.221€0.221€0.2210
€0.2340.0000.0%€0.234€0.234€0.2340
€0.234+0.015+6.8%€0.234€0.234€0.2340
€0.219-0.003-1.4%€0.219€0.219€0.2190
€0.222-0.009-3.9%€0.222€0.222€0.2220
€0.231+0.010+4.5%€0.231€0.231€0.2310
€0.221+0.005+2.3%€0.221€0.221€0.2210
€0.216-0.006-2.7%€0.216€0.216€0.2160
€0.222-0.014-5.9%€0.222€0.222€0.2220
€0.236-0.005-2.1%€0.236€0.236€0.2360
€0.241+0.010+4.3%€0.241€0.241€0.2410
€0.231-0.018-7.2%€0.231€0.231€0.2310
Ticker
Frankfurt:1C0
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All Celyad Oncology SA news

Celyad Oncology SA on 6ix

Sector
Health care
Industry
Biotechnology
News releases
6 in the last 12 months · 25 in all · newest Sep 23, 2026 · oldest 2023
Decks
28 decks · latest January 2023

Where Celyad Oncology SA is listed

ListingExchangeCountryCurrency
Euronext:CYAD · Home listingEuronextBelgiumEUR
LS Exchange:A1W7Q9LS ExchangeGermanyEUR
Lang & Schwarz:A1W7Q9Lang & SchwarzGermanyEUR
LSE:0QFKLSEUnited KingdomEUR
OTC:CLYYFOTCUnited StatesUSD
Turquoise:CYADBTurquoiseUnited KingdomEUR
Aquis:CYADBAquisUnited KingdomEUR
Aquis:CYADBAquisUnited KingdomEUR
Dusseldorf:1C0DusseldorfGermanyEUR
Frankfurt:1C0 · This pageFrankfurtGermanyEUR
Munich:1C0MunichGermanyEUR
Stuttgart:1C0StuttgartGermanyEUR

Valuation

P/E 14.6× against a median of 0.3×: the highest of 2 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
€12.04M EUR
P/E
14.6×
EV/sales
573×
EV/EBITDA
Negative EBITDA
Price/book
9.7×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Celyad Oncology SA · EURONEXT:CYADUS$13.31MUS$13.21M14.6×573×n/a9.7×n/a0.0×n/a
Actuate Therapeutics, Inc. · NASDAQ:ACTUUS$13.60MUS$11.50Mn/an/an/an/an/an/a1.75
BeyondSpring, Inc. · NASDAQ:BYSIUS$13.57MUS$12.99M0.3×n/an/a0.9×n/a0.0×1.31
Acumen Pharmaceuticals, Inc. · NASDAQ:ABOSUS$13.49M−US$38.84Mn/an/an/a0.4×n/a0.8×1.45
BioInvent International AB · OMXSTO:BINVUS$13.48M−US$6.64Mn/a−1.7×n/a0.7×n/a0.1×n/a
Pharma Equity Group A/S Class A · OMXCOP:PEGUS$13.48MUS$15.05Mn/an/a52.7×3.6×n/a0.4×n/a
Thalia Therapeutics PLC · LSE:THATUS$13.36MUS$11.39Mn/a1,199×n/a4.2×n/a0.0×n/a
Defence Therapeutics Inc Class A · CSE:DTCUS$13.27MUS$13.16Mn/an/an/a5.4×n/a0.5×0.74
Diamyd Medical AB Class B · OMXSTO:DMYD_BUS$13.24M−US$16.69Mn/a−357×n/a0.6×n/a0.0×n/a
Tvardi Therapeutics, Inc. · NASDAQ:TVRDUS$13.22M−US$9.05Mn/an/an/a0.9×n/a0.0×1.89
Devonian Health Group, Inc. · TSXV:GSDUS$13.09MUS$12.59Mn/a6.0×n/a2.7×−204.1%0.0×0.12
Median of the othersUS$13.42MUS$11.45M0.3×2.2×52.7×0.9×−204.1%0.0×1.38

Team and board

Officers

OfficerRole
Hannes IserentantGeneral Manager

Board

DirectorRole
Hilde WindelsChairwoman of the Board
Christopher LiPumaNon-Executive Director
Dominic PiscitelliIndependent Director
Jonathan JamesNon-Executive Director
Marina UdierIndependent Director
Matt KaneNon-Executive Director
Michel LussierNon-Executive Director
Sage MandelNon-Executive Director
Serge GobletNon-Executive Director
Sharon Roberg-PerezNon-Executive Director

Events

QuarterResultsShare move
Q4 2025Mar 19, 2026−2.6%
Q2 2025Sep 25, 2025+2.0%
Q2 2024Sep 13, 2024+0.6%
Q2 2023Sep 4, 2023 · After close−8.1%
Q4 2022Mar 23, 2023 · After close+4.8%
Q2 2022Aug 5, 2022 · Before open+3.1%
Q4 2021Mar 24, 2022−7.3%
Q2 2021Aug 4, 2021+0.6%
Q4 2020Mar 24, 2021−3.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (January 2023)Investor deck15 slidesJanuary 2023
Fact Sheet (June 2022)Fact sheet2 slidesJun 27, 2022
Fact Sheet (June 2022)Fact sheet1 slideJune 2022
Fact Sheet (May 2022)Fact sheet2 slidesMay 4, 2022
Fact Sheet (May 2022)Fact sheet2 slidesMay 4, 2022
Fact Sheet (May 2022)Fact sheet1 slideMay 4, 2022
Corporate Update (December 2021)Corporate update28 slidesDec 13, 2021
William Blair Growth Stock Conference 2021Conference51 slidesJul 20, 2021
European Hematology Association Virtual Congress 2021Conference24 slidesJun 11, 2021
European Hematology Association Virtual Congress 2021Conference23 slidesJun 11, 2021
All 28 decks
DeckKindSlidesDate
Fact Sheet (April 2021)Fact sheet1 slideApril 2021
Fact Sheet (March 2021)Fact sheet1 slideMarch 2021
Fact Sheet (March 2021)Fact sheet1 slideMarch 2021
Fact Sheet (March 2021)Fact sheet1 slideMarch 2021
William Blair Growth Stock Conference 2020Conference23 slidesOctober 2020
Investor Day (September 2020)Investor day56 slidesSep 29, 2020
Technical Presentation (June 2020)Technical30 slidesJune 2020
ASH 2019 Annual MeetingConference57 slidesDec 9, 2019
SITC 2019 (Society for Immunotherapy of Cancer 34th Annual Meeting)Conference50 slidesNov 9, 2019
Celyad — Investor Presentation (September 2019)Investor deck27 slidesSep 4, 2019
Investor Day (March 2019)Investor day48 slidesMar 18, 2019
Investor Presentation (January 2019)Investor deck29 slidesJanuary 2019
SITC 2018Conference9 slidesNov 9, 2018
ASGCT 2018Conference17 slidesMay 2018
Celyad — Investor Presentation (January 2018)Investor deck24 slidesJan 22, 2018
Celyad — Investor Presentation (September 2017)Investor deck29 slidesSeptember 2017
Celyad — Investor Presentation (July 2017)Investor deck33 slidesJuly 2017
Celyad — Investor Presentation (June 2017)Investor deck25 slidesJune 2017

Open Decks

Financings

RaiseDateIn US dollars
Private placement of capital increase (shares)
Closed: €500,000 raised · €0.2 a share
Buyers: CFIP CLYD (UK) Limited (€500,000 for 2,500,000 shares; expected to hold approximately 60.52% of outstanding shares and approximately 68.75% of voting rights); an affiliate of Fortress Investment Group (2,500,000 new shares)
Insiders: Fortress, a related party through its shareholding and board representation, is the subscriber; its nominated directors did not take part in the board deliberations or votes.
Use of proceeds: Working capital and general corporate purposes
Sep 23, 2026US$569,630
Private placement of newly issued ordinary shares
Announced: €1M · €0.3 a share
Buyers: CFIP CLYD (UK) Limited (€1 million for 3,333,333 newly issued ordinary shares; expected to hold approximately 58.51% of the Company's shares)
Insiders: Fortress, a related party of the Company, is the sole subscriber and is expected to hold approximately 58.51% of the shares
Use of proceeds: Working capital for general corporate purposes; extend cash runway to mid Q4 2025
Jul 28, 2025US$1.16M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue21.0K186.0K102.0K005.00K6.00K3.12M3.54M10.0M
Cost of revenue-1.91M12.0K69.0K00000515.0K1.54M
Gross profit1.93M173.0K33.0K005.00K6.00K3.12M3.02M8.47M
Research and development3.28M3.23M4.60M18.9M20.8M21.5M25.2M23.6M22.9M27.7M
Selling, general and administrative1.70M3.20M6.03M10.5M9.91M9.31M8.72M9.01M9.31M9.74M
Operating income-7.18M-5.86M-8.46M-40.9M-26.4M-17.0M-28.9M-38.2M-52.9M-25.6M
Depreciation and amortization172.0K347.0K285.0K827.0K1.30M1.64M1.79M1.11M9.00M1.52M
EBITDA-7.01M-5.51M-8.17M-40.0M-25.1M-15.4M-27.1M-37.1M-43.9M-24.1M
Interest expense64.0K119.0K84.0K198.0K255.0K434.0K343.0K62.0K144.0K109.0K
Income before tax-656.0K-5.82M-8.51M-40.9M-26.5M-17.2M-28.6M-37.4M-56.4M-23.6M
Income tax-1.49M0-63.0K65.0K10.0K0-8.00K-1.11M-1.00K-6.00K
Net income830.0K-5.82M-8.45M-40.9M-26.5M-17.2M-28.6M-37.4M-56.4M-23.6M
Earnings per share, basic0.02-0.14-0.34-1.81-1.70-1.23-2.29-3.36-5.86-2.53
Earnings per share, diluted-0.14-0.34-1.81

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents1.71M4.20M7.00M12.4M30.0M17.2M39.3M40.5M23.3M48.4M
Short-term investments00009.20M10.7M34.2M
Receivables792.0K170.0K457.0K1.12M668.0K615.0K2.70M1.27M81.0K1.11M
Inventory0417.0K1.26M1-2.14M1.56M111642.0K
Current assets3.50M6.51M11.1M14.8M34.3M19.7M42.8M51.7M36.4M85.4M
Property, plant and equipment1.49M1.83M309.0K3.25M4.12M5.06M3.01M3.29M3.56M
Goodwill00342.0K0883.0K883.0K883.0K883.0K914.0K1.04M
Total assets4.30M9.93M16.3M19.7M79.9M66.1M89.8M94.3M77.6M138.8M
Accounts payable511.0K1.23M1.24M4.75M6.61M4.74M6.97M5.92M4.80M8.10M
Current liabilities1.82M2.85M2.93M10.4M13.8M11.8M11.9M9.65M7.95M11.3M
Long-term debt00037.0K229.0K326.0K536.0K
Total debt17.5M1.06M0037.0K4.36M1.65M1.44M1.48M
Total liabilities1.86M26.0M9.98M15.4M36.3M35.1M44.2M38.7M30.1M47.9M
Shareholders' equity2.44M511.0K6.30M4.32M31.0M31.0M45.6M55.6M47.5M90.9M
Shares outstanding46.3M41.4M25.7M22.6M15.6M13.9M12.5M11.1M9.62M9.33M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-6.90M-5.68M-15.2M-28.0M-26.6M-27.7M-28.2M-27.2M-49.5M-24.7M
Capital spending00-899.0K-123.0K-331.0K-150.0K-622.0K-1.76M-858.0K-1.78M
Free cash flow-6.90M-5.68M-16.1M-28.1M-27.0M-27.8M-28.8M-29.0M-50.4M-26.5M
Cash from investing3.01M-103.0K407.0K7.20M-126.0K157.0K8.99M607.0K22.7M-30.2M
Cash from financing1.39M2.98M9.36M3.24M39.5M5.40M18.3M43.9M605.0K3.03M
Share buybacks-124.0K16.4M43.0M625.0K751.0K
Change in cash-2.49M-2.80M-5.44M-17.6M12.8M-22.1M-1.20M17.3M-25.1M-51.8M

Open Financials

Cap table

Built by 6ix from Celyad Oncology SA’s releases · as of Sep 23, 2026

Common shares
74,883,166
Fully diluted
74,883,166

Fully diluted

LineSharesAs of
Common shares74,883,166Jul 16, 2026

Share count over time

CountShares
Jul 16, 202674,883,166

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Christopher LiPumaNon-Executive Director · Since at least Nov 5, 2026
Dominic PiscitelliIndependent Director · Since at least Nov 5, 2026
Hannes IserentantGeneral Manager · Since at least Sep 23, 2026
Hilde WindelsChairwoman of the Board · Since at least Nov 5, 2026
Jonathan JamesNon-Executive Director · Since at least Nov 5, 2026
Marina UdierIndependent Director · Since at least Nov 5, 2026
Matthew KaneNon-Executive Director · Since at least Aug 26, 2025
Michel LussierNon-Executive Director · Since at least Nov 5, 2026
Rue André DumontInvestor Relations · Apr 18, 2025 – Nov 5, 2026 · Past
Sage MandelNon-Executive Director · Since at least Nov 5, 2026
All 12 people
PersonSeat
Serge GobletNon-Executive Director · Since at least Nov 5, 2026
Sharon Roberg-PerezNon-Executive Director · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Celyad Oncology SA.